ES2411907T8 - Uso terapéutico de anticuerpos antirreceptor TWEAK - Google Patents
Uso terapéutico de anticuerpos antirreceptor TWEAK Download PDFInfo
- Publication number
- ES2411907T8 ES2411907T8 ES08797148T ES08797148T ES2411907T8 ES 2411907 T8 ES2411907 T8 ES 2411907T8 ES 08797148 T ES08797148 T ES 08797148T ES 08797148 T ES08797148 T ES 08797148T ES 2411907 T8 ES2411907 T8 ES 2411907T8
- Authority
- ES
- Spain
- Prior art keywords
- tweak
- therapeutic use
- receptor antibodies
- antibodies
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95374507P | 2007-08-03 | 2007-08-03 | |
US953745P | 2007-08-03 | ||
US12362308P | 2008-04-09 | 2008-04-09 | |
US123623P | 2008-04-09 | ||
PCT/US2008/072146 WO2009020933A2 (en) | 2007-08-03 | 2008-08-04 | Therapeutic use of anti-tweak receptor antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2411907T3 ES2411907T3 (es) | 2013-07-09 |
ES2411907T8 true ES2411907T8 (es) | 2013-08-30 |
Family
ID=40193427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES08797148T Active ES2411907T3 (es) | 2007-08-03 | 2008-08-04 | Uso terapéutico de anticuerpos antirreceptor TWEAK |
Country Status (12)
Country | Link |
---|---|
US (1) | US9056908B2 (es) |
EP (2) | EP2545938A1 (es) |
JP (1) | JP5409628B2 (es) |
KR (1) | KR20100053607A (es) |
CN (1) | CN102006886A (es) |
BR (1) | BRPI0814768A2 (es) |
CA (1) | CA2694751C (es) |
ES (1) | ES2411907T3 (es) |
IL (1) | IL203038A (es) |
MX (1) | MX2010001378A (es) |
NZ (1) | NZ582815A (es) |
WO (1) | WO2009020933A2 (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1859277A4 (en) | 2005-02-17 | 2010-03-17 | Biogen Idec Inc | TREATMENT OF NEUROLOGICAL DISORDERS |
WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
BRPI0912198A2 (pt) * | 2008-05-15 | 2019-09-24 | Biogen Idec Inc | anticorpos anti-fn14 e usos dos mesmos |
ES2363669B1 (es) * | 2009-06-10 | 2012-08-09 | Fundacio Privada Institut D'investigacio Biomedica De Bellvitge (Idibell) | Metodo para determinar el riesgo de desarrollar metastasis cerebral y un kit para llevar a cabo dicho procedimiento |
CN102675460B (zh) * | 2011-02-28 | 2015-08-19 | 珠海市丽珠单抗生物技术有限公司 | 抗肿瘤坏死因子α的人源化抗体 |
AU2012225246B2 (en) * | 2011-03-10 | 2016-01-21 | Omeros Corporation | Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution |
CA2845946A1 (en) * | 2011-08-23 | 2013-02-28 | Transbio Ltd | Fn14-binding proteins and uses thereof |
AU2014203658B2 (en) * | 2011-08-23 | 2016-04-28 | La Trobe University | FN14 binding proteins and uses thereof |
WO2013166290A1 (en) * | 2012-05-04 | 2013-11-07 | Abbvie Biotherapeutics Inc. | P21 biomarker assay |
WO2013177386A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Biotherapeutics Inc. | Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy |
AU2013280644B2 (en) | 2012-06-26 | 2018-08-02 | Jeffrey A. BACHA | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
NO2760138T3 (es) | 2012-10-01 | 2018-08-04 | ||
JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び/又は副作用を低減するための方法および組成物 |
TW201534623A (zh) | 2013-06-14 | 2015-09-16 | Bayer Pharma AG | 抗-tweakr抗體及其用途 |
US9797882B2 (en) | 2013-07-09 | 2017-10-24 | The Translational Genomics Research Institute | Method of screening for a compound for inhibitory activity of FN14-tweak interaction |
US9238034B2 (en) | 2013-07-09 | 2016-01-19 | The Translational Genomics Research Institute | FN14 antagonists and therapeutic uses thereof |
ES2815098T3 (es) | 2013-12-23 | 2021-03-29 | Bayer Pharma AG | Conjugados de ligadores (ADCs) con inhibidores de KSP |
US10584175B2 (en) | 2014-10-23 | 2020-03-10 | La Trobe University | FN14-binding proteins and uses thereof |
CN107635586B (zh) * | 2014-12-15 | 2021-09-24 | 拜耳医药股份有限公司 | Ksp抑制剂与无糖基化抗-tweakr抗体的抗体-药物缀合物(adc) |
CN114917361A (zh) * | 2015-06-22 | 2022-08-19 | 拜耳医药股份有限公司 | 具有酶可裂解基团的抗体药物缀合物(adc)和抗体前药缀合物(apdc) |
US20180318438A1 (en) | 2015-06-23 | 2018-11-08 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies |
CA2990411A1 (en) | 2015-06-23 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-b7h3-antibodies |
US10973923B2 (en) * | 2015-06-23 | 2021-04-13 | Bayer Pharma Aktiengesellschaft | Site specific homogeneous with KSP inhibitors |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
KR20180123047A (ko) | 2016-03-24 | 2018-11-14 | 바이엘 파마 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물 |
EP3919518A1 (en) | 2016-06-15 | 2021-12-08 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
EP3558387B1 (de) | 2016-12-21 | 2021-10-20 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
PE20191235A1 (es) | 2016-12-21 | 2019-09-11 | Bayer Pharma AG | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente |
CN110312533B (zh) | 2016-12-21 | 2023-11-03 | 拜耳公司 | 具有酶促可裂解的基团的细胞毒性活性剂的前药 |
JP2021512103A (ja) | 2018-01-31 | 2021-05-13 | バイエル アクチェンゲゼルシャフトBayer Aktiengesellschaft | Nampt阻害剤を含む抗体薬物複合体(adcs) |
WO2020002592A1 (en) | 2018-06-29 | 2020-01-02 | Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis | Traf2 inhibitors for use in the treatment of a cancer |
SG11202104463YA (en) | 2018-10-31 | 2021-05-28 | Astellas Pharma Inc | Anti-human fn14 antibody |
WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1015477T3 (da) * | 1997-05-30 | 2011-02-07 | Human Genome Sciences Inc | 32 humane sekreterede proteiner |
US7001992B2 (en) * | 1997-05-30 | 2006-02-21 | Human Genome Sciences, Inc. | Antibodies to secreted protein HEMCM42 |
WO1998055508A2 (en) | 1997-06-03 | 1998-12-10 | Sagami Chemical Research Center | HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS |
WO1999061471A2 (en) | 1998-05-29 | 1999-12-02 | Incyte Pharmaceuticals, Inc. | Human transmembrane proteins |
EA004590B1 (ru) | 1999-01-15 | 2004-06-24 | Байоджен, Инк. | Способ блокировки развития, или снижения тяжести, или проявлений заболевания "трасплантат против хозяина" |
US6727225B2 (en) * | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
ES2433011T3 (es) * | 1999-12-20 | 2013-12-05 | Immunex Corporation | Receptor TWEAK |
US7495086B2 (en) | 1999-12-20 | 2009-02-24 | Immunex Corporation | TWEAK receptor |
WO2001070979A2 (en) | 2000-03-21 | 2001-09-27 | Millennium Pharmaceuticals, Inc. | Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer |
US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
US7208151B2 (en) * | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
CA2422095A1 (en) | 2000-09-14 | 2002-03-21 | Biogen, Inc. | Tweak receptor agonists as anti-angiogenic agents |
US7227007B2 (en) * | 2000-12-28 | 2007-06-05 | Asahi Kasei Pharma Corporation | NF-κB activating gene |
US20040214167A9 (en) * | 2000-12-28 | 2004-10-28 | Akio Matsuda | NF-kappa B activating gene |
JP4344519B2 (ja) | 2000-12-28 | 2009-10-14 | 旭化成ファーマ株式会社 | NF−κB活性化遺伝子 |
US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
KR20080106369A (ko) * | 2002-01-02 | 2008-12-04 | 제넨테크, 인크. | 종양의 진단 및 치료 방법 및 이를 위한 조성물 |
AU2003219167A1 (en) | 2002-03-19 | 2003-09-29 | Genset Sa | Treatment of metabolic disorders with a tnf receptor family member (fradj and/or cryptic) agonists or antagonists |
US20070224201A1 (en) * | 2002-10-02 | 2007-09-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
WO2004112829A2 (en) | 2003-05-23 | 2004-12-29 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumors of glial origin |
EP1648936B1 (en) * | 2003-07-24 | 2007-06-06 | Amgen Inc. | Compositions and methods relating to multimeric and oligomeric soluble fragments of the tweak receptor |
US20070298037A1 (en) * | 2003-10-16 | 2007-12-27 | Fox Brian A | ZTNFR14, A Tumor Necrosis Factor Receptor |
US7507580B2 (en) * | 2003-10-16 | 2009-03-24 | Zymogenetics, Inc. | Ztnfr14, a tumor necrosis factor receptor |
WO2005037865A2 (en) | 2003-10-16 | 2005-04-28 | Zymogenetics, Inc. | Ztnfr14, A TUMOR NECROSIS FACTOR RECEPTOR |
EP1566636A1 (en) | 2004-02-23 | 2005-08-24 | AXARON Bioscience AG | Use of Tweak modulators and inhibitors for the treatment of neurological conditions |
WO2005092383A1 (ja) | 2004-03-26 | 2005-10-06 | Takeda Pharmaceutical Company Limited | 呼吸器疾患の予防・治療剤 |
CN102225200A (zh) * | 2005-03-07 | 2011-10-26 | 健泰科生物技术公司 | 用于调控tweak和fn14活性的方法和组合物 |
JP5339901B2 (ja) * | 2005-05-10 | 2013-11-13 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 炎症傷害の処置および評価 |
WO2006125632A2 (en) * | 2005-05-24 | 2006-11-30 | Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh | Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy |
WO2006130429A2 (en) * | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
WO2006138219A2 (en) * | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
EP1876448A1 (en) | 2005-09-30 | 2008-01-09 | DIGILAB BioVisioN GmbH | Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones. |
WO2008140565A2 (en) | 2006-11-08 | 2008-11-20 | Zymogenetics, Inc. | Use of tumor necrosis factor receptor 14 antagonists for treating psoriasis |
EP2240601B1 (en) | 2007-12-27 | 2016-10-12 | Compugen Ltd. | Biomarkers for the prediction of renal injury |
EP2080812A1 (en) | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
-
2008
- 2008-08-04 EP EP12175773A patent/EP2545938A1/en not_active Withdrawn
- 2008-08-04 BR BRPI0814768-0A2A patent/BRPI0814768A2/pt not_active IP Right Cessation
- 2008-08-04 EP EP08797148A patent/EP2182982B1/en not_active Not-in-force
- 2008-08-04 MX MX2010001378A patent/MX2010001378A/es active IP Right Grant
- 2008-08-04 WO PCT/US2008/072146 patent/WO2009020933A2/en active Application Filing
- 2008-08-04 KR KR1020107004817A patent/KR20100053607A/ko not_active Application Discontinuation
- 2008-08-04 ES ES08797148T patent/ES2411907T3/es active Active
- 2008-08-04 JP JP2010519276A patent/JP5409628B2/ja not_active Expired - Fee Related
- 2008-08-04 NZ NZ582815A patent/NZ582815A/en not_active IP Right Cessation
- 2008-08-04 US US12/185,689 patent/US9056908B2/en not_active Expired - Fee Related
- 2008-08-04 CN CN2008801015223A patent/CN102006886A/zh active Pending
- 2008-08-04 CA CA2694751A patent/CA2694751C/en not_active Expired - Fee Related
-
2009
- 2009-12-29 IL IL203038A patent/IL203038A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2008284025A2 (en) | 2010-04-01 |
AU2008284025A1 (en) | 2009-02-12 |
WO2009020933A3 (en) | 2009-03-26 |
KR20100053607A (ko) | 2010-05-20 |
IL203038A (en) | 2014-03-31 |
CA2694751C (en) | 2015-07-14 |
NZ582815A (en) | 2012-07-27 |
EP2182982B1 (en) | 2013-03-27 |
MX2010001378A (es) | 2010-06-02 |
JP5409628B2 (ja) | 2014-02-05 |
WO2009020933A9 (en) | 2009-07-09 |
EP2182982A2 (en) | 2010-05-12 |
JP2010535713A (ja) | 2010-11-25 |
CA2694751A1 (en) | 2009-02-12 |
CN102006886A (zh) | 2011-04-06 |
US9056908B2 (en) | 2015-06-16 |
WO2009020933A2 (en) | 2009-02-12 |
ES2411907T3 (es) | 2013-07-09 |
BRPI0814768A2 (pt) | 2015-03-03 |
US20090074762A1 (en) | 2009-03-19 |
EP2545938A1 (en) | 2013-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2411907T8 (es) | Uso terapéutico de anticuerpos antirreceptor TWEAK | |
CY2020021I2 (el) | Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης | |
LTC2379594I2 (lt) | Žmogaus CGRP receptorių rišantys antikūnai | |
LTC2152290I2 (lt) | Anti-il-5 antikūnų skyrimo būdai | |
CY2017039I2 (el) | Αντισωματα υψηλης συγγενειας στον υποδοχεα της ανθρωπινης ιl-6 | |
BRPI0820407A2 (pt) | Uso de anticorpos anti-cd40 | |
BRPI0915928A2 (pt) | composições e métodos de uso para anticorpos terapêuticos | |
SMT201500206B (it) | Composti spiro-ossindolici e loro uso come agenti terapeutici | |
BRPI0813514A2 (pt) | anticorpos anti-cd79b humanizados e imunoconjugados e métodos de uso | |
DK2069403T3 (da) | Human-antistoffer med høj affinitet for human IL-4 receptor | |
BRPI0719210A2 (pt) | Uso de compostos espiro-oxindol como agentes terapêuticos | |
BRPI0813000A2 (pt) | Composições terapêuticas e uso das mesmas | |
CY2013046I2 (el) | Καινοτομος χρηση των αντισωματων αντι il-1bhta | |
ATE481405T1 (de) | Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors | |
BRPI0909954A2 (pt) | "diazacarbazóis e métodos de uso" | |
DK2144905T3 (da) | Terapeutiske midler | |
NO20055643D0 (no) | Preparation of lodixanol | |
NO20043305D0 (no) | Preparation of lodixanol | |
BRPI0909840A2 (pt) | Uso de 4-tio-2-deoxinucleosídios | |
DK2121138T3 (da) | Terapeutiske anvendelser af eslicarbazepin | |
BRPI0908756A2 (pt) | Uso combinado de derivado do colestanol | |
DK2301576T3 (da) | Terapeutisk anvendelse af anti-CS1-antistoffer | |
ES1065971Y (es) | Duchas de uso publico | |
UA18862S (uk) | Спинка крісла | |
ES1066260Y (es) | Bañera |